Synlogic Inc · OTC:SYBX

Synlogic — Q2 2020 Earnings Presentation

16 slides from Synlogic's earnings presentation, Aug 6, 2020

  1. Slide 1: Designed For Life: Q2 Financial Results & Business Update

    Designed For Life Q2 Financial Results & Business Update 6 August 2020 Exhibit 99.2

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in

  3. Slide 3: Opening Remarks

    © 2019 SYNLOGIC. ALL RIGHTS RESERVED. | Opening Remarks Dr. Aoife Brennan MB CHB President & CEO

  4. Slide 4: 2nd Quarter Highlights

    Julia, living with PKU 2nd Quarter Highlights We are building the premier Synthetic Biology platform to engineer bacterial Synthetic Biotic medicines that benefit patients in new ways Team, technology and portfolio to succeed: appointed Antoine Awad as COO Rapidly progressed metabolic programs SYNB1

  5. Slide 5: Advancing The Pipeline

    Advancing The Pipeline Emerging treatment options in PKU will continue to leave many patients behind SYNB1618 demonstrates potential to lower Phe in PKU patients Phase 2 Phe -lowering trial starting in 2H 2020 Next generation strain in development

  6. Slide 6: Advancing The Pipeline

    Advancing The Pipeline SYNB1891 (Synthetic Biotic for intratumoral injection) continues to enroll monotherapy cohorts SYNB1891 will provide clinical data from monotherapy cohorts in 2020 SYNB1891 has potential for improved efficacy relative to other STING approaches Emerging treatment options in PKU

  7. Slide 7: Upcoming Milestones

    Upcoming Milestones Expected Milestone 2020 2021 early mid late early mid late SYNB1618 PKU Initiate Ph.2 study in PKU patients Ph.2 Phe-lowering read-out SYNB8802 HOX Initiate IND-enabling studies initiated Initiate Ph.1 study in HV and Patients Ph.1 Patient Read-out SYNB1891 I/O Ph.1 Monotherapy r

  8. Slide 8: 2nd Quarter 2020 Summary Results

    Julia, living with PKU 2nd Quarter 2020 Summary Results Strong Cash Position With Runway Into 2022 Balance Sheet (unaudited) 30 June 2020 31 Mar 2020 Cash, Cash Equivalents, and Short & Long Term Marketable Securities $109.1M $114.3 M Statement of Operations (unaudited) 30 June 2020 30 June 2019 R&D

  9. Slide 9: Focus On Enteric Hyperoxaluria

    Focus On Enteric Hyperoxaluria Dr. Richard Riese, MD, PhD Chief Medical Officer

  10. Slide 10: Enteric Hyperoxaluria: Overview

    Enteric Hyperoxaluria: Overview Dietary Sources of Oxalate Risk Factors IBD Roux-en-Y Gastric Bypass Short Bowel Syndrome Chronic Pancreatitis Clinical Manifestations Nephrocalcinosis, Stones, and Risk of Chronic Kidney Disease Dietary Sources of Oxalate Are Difficult To Avoid, Putting Patients at R

  11. Slide 11: Hyperoxaluria: Primary vs. Enteric

    Hyperoxaluria: Primary vs. Enteric Number of Patients Affected Primary Hyperoxaluria Enteric Hyperoxaluria Pathology Family of autosomal recessive monogenic disorders in which liver enzyme deficiency results in endogenous oxalate overproduction Pathogenic hyperabsorption of dietary oxalate, often ac

  12. Slide 12: SYNB8802 Poised To Enter The Clinic

    SYNB8802 Poised To Enter The Clinic * Tasian GE, Poster SA-PO276; Kidney Week 2019 Enteric Hyperoxaluria manifests in dangerously high urinary oxalate levels, putting patients with pre-existing bowel disease at 3-4x higher risk of CKD * Differentiated profile - engineered to absorb oxalate from thro

  13. Slide 13: Enteric Hyperoxaluria: Our Next Step To Synthetic Biotic Medicines

    Enteric Hyperoxaluria Our Next Step To Synthetic Biotic Medicines High unmet medical need with no available therapeutic options Efficient clinical development: PoC achievable in Phase 1b SYNB8802 has potential to meaningfully reduce urinary oxalate levels

  14. Slide 14: Concluding Remarks

    © 2019 SYNLOGIC. ALL RIGHTS RESERVED. | Concluding Remarks Dr. Aoife Brennan MD CHB President & CEO

  15. Slide 15: Available For Questions

    Available For Questions Aoife Brennan, MD CHB President & CEO Richard Riese, MD PhD CMO Gregg Beloff, JD MBA Interim CFO Antoine Awad COO

  16. Slide 16: Synlogic contact details

    301 BINNEY ST., #402, CAMBRIDGE, MA 02142 TEL: 617-401-9975 WEB: WWW.SYNLOGICTX.COM EMAIL: INFO@SYNLOGICTX.COM © SYNLOGIC. ALL RIGHTS RESERVED.

Synlogic — Q2 2020 Earnings Presentation on 6ix